Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28251367 | 0.80 | DYRK1A (0.60) | DYRK1ACA12CA1CA2CA3 | |
| SCHEMBL15617054 | 0.75 | DYRK1A (0.55) | DYRK1ASLC6A4HTR2ACYP1A2CYP2A6 | |
| SCHEMBL1012163 | 0.75 | IMPDH2 (0.50) | DYRK1ACA12CA1CA2CA3 | |
| SCHEMBL31188784 | 0.75 | DYRK1A (0.55) | DYRK1ACLK1CDK5CDK5R1GSK3B | |
| SCHEMBL12865280 | 0.75 | TRIM24 (0.55) | DYRK1ACA12CA1CA2CA3 | |
| SCHEMBL13544614 | 0.75 | DYRK1A (0.55) | DYRK1ACA12CA9CLK1CDK5 | |
| SCHEMBL19836840 | 0.75 | DYRK1A (0.55) | DYRK1ACLK1CDK5CDK5R1GSK3B | |
| SCHEMBL1137500 | 0.75 | DYRK1A (0.55) | DYRK1ACLK1CDK5CDK5R1GSK3B | |
| SCHEMBL21636392 | 0.75 | DYRK1A (0.55) | DYRK1ACA12CA9CLK1CDK5 | |
| SCHEMBL31049262 | 0.75 | DYRK1A (0.55) | DYRK1ACLK1CDK5CDK5R1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390387-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-28 | — | — | US | disclosed |
| US-12102641-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-10-01 | — | — | US | disclosed |
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-02-06 | — | — | US | disclosed |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-16 | — | — | US | disclosed |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-16 | — | — | US | disclosed |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-16 | — | — | US | disclosed |
| US-20230146717-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146717-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146717-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-4105220-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2022-12-21 | — | — | EP | disclosed |
| EP-4105220-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2022-12-21 | — | — | EP | disclosed |
| CN-115087658-A | Sulfonamide or sulfenamide compounds having BRD 4-inducing proteolytic activity, and pharmaceutical use thereof | 田边三菱制药株式会社 | 2022-09-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11890288-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | BRD4, BRD1, BRD2 | DYRK1A 2345/4885CA12 4426/4885CA1 4480/4885 |
| US-20230146717-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | DYRK1A 2345/4885CA12 4426/4885CA1 4480/4885 |
| US-20230364105-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | DYRK1A 2345/4885CA12 4426/4885CA1 4480/4885 |
| US-12102641-B2 | Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof | BRD4, BRD1, BRD2 | DYRK1A 2345/4885CA12 4426/4885CA1 4480/4885 |
| US-20240390387-A1 | SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF | BRD4, BRD1, BRD2 | DYRK1A 2345/4885CA12 4426/4885CA1 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.